Kiora Pharmaceuticals: Alyeska reports 4.99% ownership
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kiora Pharmaceuticals, Inc. (KPRX) is the issuer in an amended beneficial-ownership report in which Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh each report the same 220,776-share position in common stock issuable upon warrant exercise, equal to 4.99% of the class as of September 30, 2026.
The position is held by Alyeska Master Fund, L.P.; Alyeska Investment Group, as investment manager, exercises voting and investment control. Parekh, the investment group's Chief Executive Officer, may be deemed a beneficial owner and disclaims beneficial ownership. The reporting persons hold warrants exercisable for 596,854 shares, but a beneficial ownership limitation permits exercise of only 220,776 warrant shares. Kiora had 4,424,387 common shares outstanding as of August 7, 2026.
Key Figures
Key Terms
beneficial ownership limitation technical
investment control technical
warrants financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How does the KPRX warrant ownership limit work?
AI-generated analysis. How Rhea-AI works. Not financial advice.